The estimated Net Worth of Steven G Finn is at least $2.4 Миллион dollars as of 1 November 2012. Steven Finn owns over 25,000 units of Opiant Pharmaceuticals Inc stock worth over $2,395,400 and over the last 21 years Steven sold OPNT stock worth over $0.
Sign up
Steven Finn OPNT stock SEC Form 4 insiders trading
Steven has made over 6 trades of the Opiant Pharmaceuticals Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently Steven exercised 25,000 units of OPNT stock worth $363,750 on 1 November 2012.
The largest trade Steven's ever made was exercising 30,000 units of Opiant Pharmaceuticals Inc stock on 8 November 2010 worth over $210,000. On average, Steven trades about 6,176 units every 191 days since 2003. As of 1 November 2012 Steven still owns at least 116,000 units of Opiant Pharmaceuticals Inc stock.
You can see the complete history of Steven Finn stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Steven Finn's mailing address?
Steven's mailing address filed with the SEC is C/O OPNET TECHNOLOGIES, INC., 7255 WOODMONT AVENUE, BETHESDA, MD, 20814.
Insiders trading at Opiant Pharmaceuticals Inc
Over the last 21 years, insiders at Opiant Pharmaceuticals Inc have traded over $16,027,532 worth of Opiant Pharmaceuticals Inc stock and bought 199,545 units worth $2,080,156 . The most active insiders traders include Craig A Collard, Marc A Cohen и Alain J Cohen. On average, Opiant Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $159,046. The most recent stock trade was executed by Roger Crystal on 27 January 2023, trading 1,358 units of OPNT stock currently worth $27,513.
What does Opiant Pharmaceuticals Inc do?
Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.
What does Opiant Pharmaceuticals Inc's logo look like?
Complete history of Steven Finn stock trades at Opiant Pharmaceuticals Inc
Opiant Pharmaceuticals Inc executives and stock owners
Opiant Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Roger Crystal,
President, Chief Executive Officer, Director -
Michael Sinclair,
Executive Chairman of the Board -
Dr. Roger Crystal,
Pres, CEO & Director -
Dr. Phil Skolnick D.Sc. (hon), Ph.D.,
Chief Scientific Officer -
David D. O'Toole,
Chief Financial Officer -
Michael Porter,
IR Contact Officer -
Richard Daly,
Independent Director -
Craig Collard,
Independent Director -
Thomas Thomas,
Director -
Gabrielle Silver,
Director -
Ann MacDougall,
Director -
Aziz Mottiwala,
Chief Commercial Officer -
Rahsaan Thompson,
General Counsel -
Phil Skolnick,
Chief Scientific Officer -
Arvind Agrawal,
Executive Vice President - Medical Affairs -
David O'Toole,
Chief Financial Officer -
Matthew R. Ruth,
Chief Commercial Officer -
Dr. Mark Heath Ellison Ph.D.,
Chief Devel. Officer -
Brian Gorman,
EVP Corp. Devel. & Gen. Counsel -
Ben Atkins,
VP of Communications & Investor Relations -
Matthew R. Ruth,
Chief Commercial Officer -
Ronald W Kaiser,
Director -
Melvin Iii Wesley,
Chief Financial Officer -
William F Stasior,
Director -
Steven G Finn,
Director -
Joseph W Kuhn,
VP & Chief Financial Officer -
Alain J Cohen,
President & Chief Tech Officer -
Marc A Cohen,
Chairman, CEO, Treas, & Sec -
Brian Gorman,
-
Mark Jason Heath Ellison,
Chief Development Officer -
Masuoka K. Lorianne,
Director